PMC:7102560 / 9322-11320
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T41 | 1739-1743 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T42 | 1777-1789 | Body_part | denotes | interleukins | http://purl.org/sig/ont/fma/fma86578 |
| T43 | 1832-1836 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T118 | 72-80 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T119 | 72-76 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T120 | 120-128 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T121 | 120-124 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T122 | 817-825 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T123 | 817-821 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T124 | 856-864 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T125 | 856-860 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T126 | 973-981 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T127 | 973-977 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T128 | 1014-1022 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T129 | 1014-1018 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T130 | 1189-1197 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T131 | 1189-1193 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T132 | 1366-1374 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T133 | 1366-1370 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T134 | 1940-1959 | Disease | denotes | immune dysfunctions | http://purl.obolibrary.org/obo/MONDO_0005046 |
| T135 | 1974-1982 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T136 | 1974-1978 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T73 | 314-318 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
| T74 | 1652-1653 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T75 | 1739-1743 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T76 | 1830-1836 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B cell |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T27 | 1120-1129 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T28 | 1139-1150 | Chemical | denotes | Oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
| T29 | 1236-1245 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T30 | 1722-1729 | Chemical | denotes | steroid | http://purl.obolibrary.org/obo/CHEBI_35341 |
| T31 | 1777-1789 | Chemical | denotes | interleukins | http://purl.obolibrary.org/obo/CHEBI_52998 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 1739-1761 | http://purl.obolibrary.org/obo/GO_0002456 | denotes | cell-mediated immunity |
| T3 | 1739-1761 | http://purl.obolibrary.org/obo/GO_0002449 | denotes | cell-mediated immunity |
| T4 | 1777-1800 | http://purl.obolibrary.org/obo/GO_0001816 | denotes | interleukins production |
| T5 | 1830-1850 | http://purl.obolibrary.org/obo/GO_0042100 | denotes | B cell proliferation |
| T6 | 1832-1850 | http://purl.obolibrary.org/obo/GO_0008283 | denotes | cell proliferation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T123 | 0-96 | Sentence | denotes | We need better data to determine risk factors and mechanisms that cause SARS-CoV-2 reactivation. |
| T124 | 97-256 | Sentence | denotes | The timing of onset of SARS-CoV-2 reactivation can be variable depending upon the host factors, underlying disease and the type of immunosuppressive therapies. |
| T125 | 257-343 | Sentence | denotes | In our study, the recovered patients had positive RT-PCR test results 4–17 days later. |
| T126 | 344-494 | Sentence | denotes | The key risk factors for reactivation would include 3 categories: (1) host status, (2) virologic factors and (3) type and degree of immunosuppression. |
| T127 | 495-578 | Sentence | denotes | Host factors may include sex, older age, type of disease needing immunosuppression. |
| T128 | 579-725 | Sentence | denotes | Although we could not identify risk factors for these host factors in the current study, the potential requires further large cohort confirmation. |
| T129 | 726-855 | Sentence | denotes | The virologic factors associated with increased risk of reactivation include high baseline SARS-CoV-2 load and variable genotype. |
| T130 | 856-1079 | Sentence | denotes | SARS-CoV-2 viral load would also linked to treatment response, disease severity and progression.8 The association of SARS-CoV-2 genotypes and viral load with SARS-CoV-2 reactivation will be an important question to address. |
| T131 | 1080-1163 | Sentence | denotes | In our study, all the patients received antiviral therapy (Oseltamivir or Arbidol). |
| T132 | 1164-1259 | Sentence | denotes | These cases suggest that SARS-CoV-2 reactivation may occur whatever the antiviral therapy used. |
| T133 | 1260-1390 | Sentence | denotes | These host and virologic factors are important considerations that may further increase the likelihood of SARS-CoV-2 reactivation. |
| T134 | 1391-1565 | Sentence | denotes | Therefore, the assessment of host as well as virologic risk factors should be important caveats to help decide whether to initiate prophylactic therapy and immunosuppression. |
| T135 | 1566-1633 | Sentence | denotes | Immunosuppressive therapies are the commonly used causative agents. |
| T136 | 1634-1708 | Sentence | denotes | These agents have a general mechanism that inhibits many immune functions. |
| T137 | 1709-1998 | Sentence | denotes | For example, steroid inhibits cell-mediated immunity by suppressing interleukins production which is important for T and B cell proliferation.9 It is thus not surprising that these general immunosuppressive effects result in broad immune dysfunctions and potential SARS-CoV-2 reactivation. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 332 | 72-82 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 333 | 120-130 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 334 | 285-293 | Species | denotes | patients | Tax:9606 |
| 335 | 817-827 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 336 | 856-866 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 337 | 973-983 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 338 | 1014-1024 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 339 | 1189-1199 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 340 | 1366-1376 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 341 | 1974-1984 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 342 | 1102-1110 | Species | denotes | patients | Tax:9606 |
| 343 | 1139-1150 | Chemical | denotes | Oseltamivir | MESH:D053139 |
| 344 | 1154-1161 | Chemical | denotes | Arbidol | MESH:C086979 |
| 345 | 1722-1729 | Chemical | denotes | steroid | MESH:D013256 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32171867-17293163-61116998 | 1851-1852 | 17293163 | denotes | 9 |